Pfizer EPS (Diluted, Continuing) decreased by 22.6% to $0.48 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.7%, from $0.52 to $0.48. Over 2 years (FY 2021 to FY 2024), EPS (Diluted, Continuing) shows a downward trend with a -40.3% CAGR.
mrk_eps_diluted_continuing_operations| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.04 | $1.45 | $0.63 | $1.40 | $1.76 | $1.54 | $0.89 | $0.98 | $0.41 | -$0.42 | $0.55 | $0.01 | $0.79 | $0.07 | $0.52 | $0.51 | $0.62 | $0.48 |
| QoQ Change | — | +39.4% | -56.6% | +122.2% | +25.7% | -12.5% | -42.2% | +10.1% | -58.2% | -202.4% | +231.0% | -98.2% | >999% | -91.1% | +642.9% | -1.9% | +21.6% | -22.6% |
| YoY Change | — | — | — | — | +69.2% | +6.2% | +41.3% | -30.0% | -76.7% | -127.3% | -43.9% | -97.6% | +288.1% | — | -5.5% | >999% | -21.5% | -7.7% |